52378-71-9

Upstream product

• 100-39-0 benzyl bromide 
• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 110506-85-9 7-(benzyloxy)-5-hydroxy-2-phenyl-4H-chromen-4-one 
• 681294-57-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethanone 
• 39548-89-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethan-1-one 
• 25892-94-8 1-(4-(benzyloxy)-3,6-dihydroxy-2-methoxyphenyl)ethan-1-one 
• 25892-95-9 1-(4-(benzyloxy)-6-hydroxy-2,3-dimethoxyphenyl)ethan-1-one 
• 52378-70-8 (E)-1-(4-Benzyloxy-6-hydroxy-2,3-dimethoxy-phenyl)-3-(3,4-dimethoxy-phenyl)-propenone 

Downstream Products

• 40983-99-1 2-(3,4-dimethoxyphenyl)-7-hydroxy-5,6-dimethoxy-4H-chromen-4-one 
• 22368-21-4 eupatilin 

Relevant academic research and scientific papers

Novel compound and composition for prevention, improvement or treatment of fibrosis or non-alcoholic steatohepatitis comprising the same

The present invention relates to a novel compound and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. More specifically, the present invention relates to a novel compound of chemical formula 1 which has an excellent effect for prevention, improvement, or treatment of fibrosis and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. A novel compound of the present invention effectively controls expression of snail and vimentin which are a controlling element of Epithelial Mesenchymal Transition (EMT) and controls activation of EMT, and thus effectively prevents, improves, or treats fibrosis accordingly. Additionally, a novel compound of the present invention has a very excellent pharmacokinetic characteristic, and thus can perform fast drug delivery to the body through oral administration, stably displays an effect in the body, and is secure to use without a big side effect. Moreover, since a novel compound of the present invention can effectively block fibrosis of a hepatic cell, nonalcoholic steatohepatitis can effectively improved or treated.(AA) Chemical formula 1COPYRIGHT KIPO 2018

USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY

A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease

PCT No. PCT/KR97/00144 Sec. 371 Date Jan. 14, 1999 Sec. 102(e) Date Jan. 14, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/04541 PCT Pub. Date Feb. 5, 1998The present invention relates to novel flavone/flavanone compounds or their pharmaceutically acceptable salts and process for preparation thereof for protecting gastrointestinal tracts against gastritis, ulcers and inflammatory bowel disease.